

# Beat Mullhaupt

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6712133/publications.pdf>

Version: 2024-02-01

95  
papers

5,066  
citations

196777

29  
h-index

104191

69  
g-index

104  
all docs

104  
docs citations

104  
times ranked

8854  
citing authors

#	ARTICLE	IF	CITATIONS
1	A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. <i>Journal of Hepatology</i> , 2022, 76, 275-282.	1.8	33
2	HCV disease burden and population segments in Switzerland. <i>Liver International</i> , 2022, 42, 330-339.	1.9	14
3	Evaluation of a structured treatment discontinuation in patients with inoperable alveolar echinococcosis on long-term benzimidazole therapy: A retrospective cohort study. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010146.	1.3	11
4	Increasing prevalence of obesity and diabetes among patients evaluated for liver transplantation in a Swiss tertiary referral center: a 10-year retrospective analysis. , 2022, 152, w30138.		0
5	Characteristics and Clinical Course of Alveolar Echinococcosis in Patients with Immunosuppression-Associated Conditions: A Retrospective Cohort Study. <i>Pathogens</i> , 2022, 11, 441.	1.2	3
6	Serological Assays for Alveolar and Cystic Echinococcosis – A Comparative Multi-Test Study in Switzerland and Kyrgyzstan. <i>Pathogens</i> , 2022, 11, 518.	1.2	7
7	The essential requirements for an HPB centre to deliver high-quality outcomes. <i>Journal of Hepatology</i> , 2022, 77, 837-848.	1.8	2
8	Protein Tyrosine Phosphatase Nonreceptor Type 2 Expression Does Not Correlate with Viral Load or Response to Direct-Acting Antiviral Therapy in Hepatitis C Virus Infections-Infected Patients. <i>Digestion</i> , 2021, 102, 453-461.	1.2	1
9	Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1 – 3 Infections. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 195-198.e2.	2.4	12
10	Real-world effectiveness and safety of glecaprevir/pibrentasvir therapy in patients with chronic hepatitis C virus infection in Switzerland. <i>Swiss Medical Weekly</i> , 2021, 151, w20399.	0.8	4
11	Adherence to, and patient convenience of, prolonged-release tacrolimus in stable kidney and liver transplant recipients after conversion from immediate-release tacrolimus in routine clinical practice in Switzerland. <i>Swiss Medical Weekly</i> , 2021, 151, w20453.	0.8	4
12	When <i>Echinococcus granulosus</i> transmigrates from the liver into the pericardium: a case report. <i>Journal of Surgical Case Reports</i> , 2021, 2021, rjaa492.	0.2	2
13	Autochthonous hepatitis E as a cause of acute-on-chronic liver failure and death: histopathology can be misleading but transaminases may provide a clue. <i>Swiss Medical Weekly</i> , 2021, 151, w20502.	0.8	2
14	Rates of Hepatocellular Carcinoma After Start of Treatment for Chronic Hepatitis C Remain High with Direct Acting Antivirals: Analysis from a Swiss Liver Transplant Center. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 565-574.	1.8	1
15	Association between environmental and climatic risk factors and the spatial distribution of cystic and alveolar echinococcosis in Kyrgyzstan. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009498.	1.3	5
16	Secondary sclerosing cholangitis as cause of persistent jaundice in patients with severe COVID-19. <i>Liver International</i> , 2021, 41, 2404-2417.	1.9	58
17	Pilot Sub-Study of the Effect of Hepatitis C Cure by Glecaprevir/Pibrentasvir on the Gut Microbiome of Patients with Chronic Hepatitis C Genotypes 1 to 6 in the Mythen Study. <i>Pharmaceuticals</i> , 2021, 14, 931.	1.7	5
18	Recanalization of Chronic Noncirrhotic, Nonmalignant Splanchnic Thromboses is Feasible: A Transsplenic Assisted Patient-Tailored Approach. <i>Journal of Vascular and Interventional Radiology</i> , 2021, 32, 1377-1385.	0.2	6

#	ARTICLE	IF	CITATIONS
19	Pathology of Echinococcosis. American Journal of Surgical Pathology, 2020, 44, 43-54.	2.1	46
20	The <sup>13</sup> C-methactin breath test is non-inferior to liver biopsy in predicting liver-related death and transplantation: A 7-year prospective follow-up study in 132 patients with chronic hepatitis C infection. GastroHep, 2020, 2, 344-350.	0.3	2
21	Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen. Journal of Antimicrobial Chemotherapy, 2020, 75, 3349-3358.	1.3	13
22	Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection. Journal of Viral Hepatitis, 2020, 27, 974-986.	1.0	12
23	Genetic diversity of Echinococcus multilocularis and Echinococcus granulosus sensu lato in Kyrgyzstan: The A2 haplotype of E. multilocularis is the predominant variant infecting humans. PLoS Neglected Tropical Diseases, 2020, 14, e0008242.	1.3	19
24	Epidemic cystic and alveolar echinococcosis in Kyrgyzstan: an analysis of national surveillance data. The Lancet Global Health, 2020, 8, e603-e611.	2.9	35
25	A prospective, multicenter, post-marketing observational study to measure the quality of life of HCV genotype 1 infected, treatment naïve patients suffering from fatigue and receiving 3D regimen: The HEMATITE study. PLoS ONE, 2020, 15, e0241267.	1.1	2
26	Infected Extrahepatic Splanchnic Venous Stent(-Grafts): Clinical Presentation, Imaging, and Treatment in Three Patients. Journal of Vascular and Interventional Radiology, 2020, 31, 754-758.	0.2	1
27	Title is missing!. , 2020, 15, e0241267.		0
28	Title is missing!. , 2020, 15, e0241267.		0
29	Title is missing!. , 2020, 15, e0241267.		0
30	Title is missing!. , 2020, 15, e0241267.		0
31	Title is missing!. , 2020, 15, e0241267.		0
32	Title is missing!. , 2020, 15, e0241267.		0
33	Impact of geographic origin on access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study. PLoS ONE, 2019, 14, e0218706.	1.1	4
34	A rare cause of a cholestatic jaundice in a North African teenager. Liver International, 2019, 39, 2036-2041.	1.9	4
35	Identification of an Endoglin Variant Associated With HCV-Related Liver Fibrosis Progression by Next-Generation Sequencing. Frontiers in Genetics, 2019, 10, 1024.	1.1	6
36	Human genomics of acute liver failure due to hepatitis B virus infection: An exome sequencing study in liver transplant recipients. Journal of Viral Hepatitis, 2019, 26, 271-277.	1.0	4

#	ARTICLE	IF	CITATIONS
37	Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions. <i>Swiss Medical Weekly</i> , 2019, 149, w14694.	0.8	7
38	MRI and PET-CT Failed to Differentiate Between Hepatic Malignancy and Brucelloma. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy052.	0.4	1
39	Evaluation of kinase-inhibitors nilotinib and everolimus against alveolar echinococcosis inÂvitro and in a mouse model. <i>Experimental Parasitology</i> , 2018, 188, 65-72.	0.5	10
40	Patterns of Resistance-Associated Substitutions in Patients WithÂChronic HCV Infection Following Treatment With Direct-Acting Antivirals. <i>Gastroenterology</i> , 2018, 154, 976-988.e4.	0.6	132
41	Hepatitis E blood donor screening â€“ More than a mere drop in the ocean?. <i>Journal of Hepatology</i> , 2018, 69, 8-10.	1.8	5
42	Hepatitis E virus as a cause of acute hepatitis acquired in Switzerland. <i>Liver International</i> , 2018, 38, 619-626.	1.9	25
43	Targeting senescent cholangiocytes and activated fibroblasts with Bâ€cell lymphomaâ€™extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout (Mdr2âˆ/âˆ) mice. <i>Hepatology</i> , 2018, 67, 247-259.	3.6	99
44	IDDF2018-ABS-0109â€™...SOFOSBUVIR/VELPATASVIR for 12 weeks in genotype 1â€™4 hcv-infected liver transplant recipients. , 2018, , .		0
45	Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?. <i>PLoS ONE</i> , 2018, 13, e0209374.	1.1	12
46	Serum IP-10 levels and increased DPPIV activity are linked to circulating CXCR3+ T cells in cholestatic HCV patients. <i>PLoS ONE</i> , 2018, 13, e0208225.	1.1	3
47	Liver Allograft Failure After Nivolumab Treatmentâ€™A Case Report With Systematic Literature Research. <i>Transplantation Direct</i> , 2018, 4, e376.	0.8	98
48	Treatment of non-alcoholic steatohepatitis patients with vitamin D: a double-blinded, randomized, placebo-controlled pilot study. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 1114-1120.	0.6	41
49	Sofosbuvir/velpatasvir for 12â€™weeks in genotype 1â€™4 HCV-infected liver transplant recipients. <i>Journal of Hepatology</i> , 2018, 69, 603-607.	1.8	58
50	Recurrence of Hepatitis B Infection in Liver Transplant Patients Receiving Long-Term Hepatitis B Immunoglobulin Prophylaxis. <i>Annals of Transplantation</i> , 2018, 23, 789-801.	0.5	17
51	Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland. <i>Swiss Medical Weekly</i> , 2018, 148, w14560.	0.8	10
52	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 161-176.	3.7	1,619
53	A systematic review and metaâ€™analysis of <sc>HCV</sc> clearance. <i>Liver International</i> , 2017, 37, 1431-1445.	1.9	37
54	Visualization of hepatitis E virus RNA and proteins in the human liver. <i>Journal of Hepatology</i> , 2017, 67, 471-479.	1.8	49

#	ARTICLE	IF	CITATIONS
55	A Dual Role of Caspase-8 in Triggering and Sensing Proliferation-Associated DNA Damage, a Key Determinant of Liver Cancer Development. <i>Cancer Cell</i> , 2017, 32, 342-359.e10.	7.7	122
56	Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis score and aspartate aminotransferase-platelet ratio index. <i>Liver International</i> , 2017, 37, 369-376.	1.9	207
57	Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030. <i>Swiss Medical Weekly</i> , 2017, 147, w14543.	0.8	12
58	Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant. <i>Annals of Hepatology</i> , 2017, 16, 375-381.	0.6	1
59	Development of OXY111A, a novel hypoxia-modifier as a potential antitumor agent in patients with hepato-pancreato-biliary neoplasms - Protocol of a first Ib/IIa clinical trial. <i>BMC Cancer</i> , 2016, 16, 812.	1.1	18
60	Canonical NF- $\kappa$ B signaling in hepatocytes acts as a tumor suppressor in hepatitis B virus surface antigen-driven hepatocellular carcinoma by controlling the unfolded protein response. <i>Hepatology</i> , 2016, 63, 1592-1607.	3.6	51
61	Fatal Liver and Lung Alveolar Echinococcosis with Newly Developed Neurologic Symptoms due to the Brain Involvement. <i>The Surgery Journal</i> , 2016, 02, e83-e88.	0.3	7
62	Liver cancer with concomitant TP53 and CTNNB1 mutations: a case report. <i>BMC Clinical Pathology</i> , 2016, 16, 7.	1.8	9
63	Orbital Pseudotumor as a Rare Extrahepatic Manifestation of Hepatitis C Infection. <i>Case Reports in Gastroenterology</i> , 2016, 10, 113-119.	0.3	5
64	Alterations in Enterohepatic Fgf15 Signaling and Changes in Bile Acid Composition Depend on Localization of Murine Intestinal Inflammation. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 2382-2389.	0.9	21
65	Liver retransplantation with cavoportal hemitransposition after percutaneous mesocaval shunt creation. <i>Liver Transplantation</i> , 2016, 22, 1154-1158.	1.3	1
66	A significant effect of the killer cell immunoglobulin-like receptor ligand human leucocyte antigen-C on fibrosis progression in chronic C hepatitis with or without liver transplantation. <i>Liver International</i> , 2016, 36, 1331-1339.	1.9	4
67	Symptoms of Depression and Anxiety Are Independently Associated With Clinical Recurrence of Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 829-835.e1.	2.4	260
68	Polymorphisms in the lectin pathway of complement activation influence the incidence of acute rejection and graft outcome after kidney transplantation. <i>Kidney International</i> , 2016, 89, 927-938.	2.6	37
69	Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Infectious Diseases</i> , 2016, 16, 685-697.	4.6	402
70	Modelling the impact of deferring HCV treatment on liver-related complications in HIV coinfecting men who have sex with men. <i>Journal of Hepatology</i> , 2016, 65, 26-32.	1.8	26
71	Correlation between Dual-Energy and Perfusion CT in Patients with Hepatocellular Carcinoma. <i>Radiology</i> , 2016, 280, 78-87.	3.6	65
72	Characteristics of Foreign-Born Persons in the Swiss Hepatitis C Cohort Study: Implications for Screening Recommendations. <i>PLoS ONE</i> , 2016, 11, e0155464.	1.1	9

#	ARTICLE	IF	CITATIONS
73	Influence of Ribavirin Serum Levels on Outcome of Antiviral Treatment and Anemia in Hepatitis C Virus Infection. <i>PLoS ONE</i> , 2016, 11, e0158512.	1.1	9
74	A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearance. <i>Hepatology</i> , 2015, 62, 1375-1387.	3.6	25
75	Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland. <i>PLoS ONE</i> , 2015, 10, e0125214.	1.1	25
76	Outcome after Discontinuing Long-Term Benzimidazole Treatment in 11 Patients with Non-resectable Alveolar Echinococcosis with Negative FDG-PET/CT and Anti-Emll/3-10 Serology. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003964.	1.3	52
77	A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients. <i>PLoS ONE</i> , 2015, 10, e0133028.	1.1	18
78	Progression of Liver Fibrosis in HIV/HCV Co-Infection: A Comparison between Non-Invasive Assessment Methods and Liver Biopsy. <i>PLoS ONE</i> , 2015, 10, e0138838.	1.1	38
79	Reply to Cunha et al. <i>Clinical Infectious Diseases</i> , 2015, 61, 1894-1895.	2.9	0
80	Efficacy and Safety of Faldaprevir, Deleobuvir, and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis C Virus Infection and Advanced Liver Fibrosis or Cirrhosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1282-1291.	1.4	10
81	Molecular detection of hepatitis E virus (HEV) in liver biopsies after liver transplantation. <i>Modern Pathology</i> , 2015, 28, 523-532.	2.9	36
82	Challenges to Liver Transplantation and Strategies to Improve Outcomes. <i>Gastroenterology</i> , 2015, 148, 307-323.	0.6	208
83	Cost-Effectiveness Analysis of Sofosbuvir Compared to Current Standard Treatment in Swiss Patients with Chronic Hepatitis C. <i>PLoS ONE</i> , 2015, 10, e0126984.	1.1	36
84	ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection. <i>PLoS ONE</i> , 2015, 10, e0144004.	1.1	5
85	Birth cohort distribution and screening for viraemic hepatitis C virus infections in Switzerland. <i>Swiss Medical Weekly</i> , 2015, 145, w14221.	0.8	8
86	Reduced IFN $\gamma$ 4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. <i>Nature Communications</i> , 2014, 5, 5699.	5.8	117
87	Late biliary complications in human alveolar echinococcosis are associated with high mortality. <i>World Journal of Gastroenterology</i> , 2014, 20, 5881.	1.4	26
88	HOPE for human liver grafts obtained from donors after cardiac death. <i>Journal of Hepatology</i> , 2014, 60, 765-772.	1.8	278
89	Is tumor biopsy necessary?. <i>Liver Transplantation</i> , 2011, 17, S14-S25.	1.3	38
90	Hot topics in liver transplantation: Organ allocation "extended criteria donor" living donor liver transplantation. <i>Journal of Hepatology</i> , 2008, 48, S58-S67.	1.8	52

#	ARTICLE	IF	CITATIONS
91	Alveolar echinococcosis: From a deadly disease to a well-controlled infection. Relative survival and economic analysis in Switzerland over the last 35 years. <i>Journal of Hepatology</i> , 2008, 49, 72-77.	1.8	215
92	Mortality from primary liver cancer in Switzerland from 1975 to 1994. <i>Swiss Medical Weekly</i> , 2008, 138, 313-6.	0.8	2
93	Successful use of the Molecular Adsorbent Recirculating System (MARS) in a patient with primary biliary cirrhosis (PBC) and treatment refractory pruritus. <i>Hepatology Research</i> , 2003, 25, 442-446.	1.8	24
94	Simulation of hepatitis C based on a mandatory reporting system. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 25-34.	0.8	41
95	5â€²-Cytosine DNA-methyltransferase mRNA levels in hereditary colon carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 1999, 434, 57-62.	1.4	4